Blog

09.02.2017

CEFFs provide biotech companies with more control over the issuance of new shares

Similarly, although CEFFs provide biotech companies with more control over the issuance of new shares at fair prices, CEFFs still require issuing equity at prices that […]
09.02.2017

Biotech can issue the new shares

  Royalty streams. One such alternative is the sale of royalty streams on future product sales of commercial or very late-stage clinical candidates to institutional investors […]
09.02.2017

Transaction Advisory Services for Healthcare Service Companies

Securing adequate funding for drug discovery and development programs continues to be challenging for the biotech industry. Historically, such funding has been raised through dilutive equity […]
09.02.2017

A Glimpse into the Future of White Biotechnology

Although reality could not come up with the forecasted impacts of white biotech on traditional chemical production processes, it is more a question of when but […]
09.02.2017

The Capital Market’s Perception – White versus Red

Whereas Red Biotechnology is already accepted by the capital markets and dominates by far the total number of biotechnology companies, there are only few dedicated white […]